Neil Fanger, PhD – Chairman and CEO

Neil Fanger has over 17 years of experience in the life sciences industry, spanning business development, product strategy, and biological research. Prior to Virtici, Dr. Fanger co-founded Teranode Corporation (acquired by Rage Frameworks in 2010). At Teranode, he led teams that introduced new products into the marketplace and secured worldwide partnerships with strategic customers such as Pfizer, AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline. Prior to Teranode, Dr. Fanger focused on product development at Corixa and Immunex. Dr. Fanger is co-inventor on several patents covering novel biological therapeutics and software technologies, and co-author on numerous research publications in leading scientific journals. He earned a PhD in physiology from Dartmouth Medical School, and a BS in chemistry from Denison University.

Michael W. Fanger, PhD - Director

Michael Fanger is currently Founder, Chairman, and CSO of Celdara Medical, LLC. Prior to Celdara, Dr. Fanger was co-founder, President and Chief Executive Officer of Celldex Therapeutics Inc. (NASDAQ: CLDX), as well as the co-founder and Director of Medarex, Inc. (previously NASDAQ: MEDX, acquired by BMS in 2009) from its inception in 1987 until 2004. Dr. Fanger has been a Professor of Microbiology and Immunology and Medicine at Dartmouth Medical School since 1981, and was a Chairman of the Department of Microbiology and Immunology from 1992 until 2002. Dr. Fanger is co-inventor on 91 patents covering novel biological therapeutics and software technologies, and co-author on 160 research publications in leading scientific journals. He is a graduate of Wabash College with a BS in Chemistry and received his PhD in Biochemistry from Yale University.

Jake Reder, PhD - Director

Jake cofounded Celdara Medical and currently serves as a Director and as CEO. He had previously founded the New Ventures Office at Dartmouth Medical School and still serves as its first Director. Prior to Dartmouth, Jake led business development, open innovation, and knowledge management initiatives at Cabot Corporation where he served as a member of Cabot’s Research Council, Technology Board, and Nanotechnology EHS Council. Jake joined Cabot from PolyTechnos Venture-Partners, a Munich-based venture capital firm. He has served on numerous non- and for-profit boards, including Virtici, MBV, StemSynergy Therapeutics, NIH’s TREAT Program and the University of Vermont’s SPARK Program. Jake has testified before Congress on entrepreneurship, was appointed by the Governor to the New Hampshire Innovation Research Center’s Board of Directors, and by US Senator Jeanne Shaheen to her Small Business Advisory Council. Jake earned a B.Sc. with First Class Honours from the University of Waterloo, and a Ph.D. (Chemistry) as a Brown-Wetherill Fellow at Purdue University and Ludwig Maximilians Universität.

Gary Fanger, PhD – Director

Gary Fanger is currently President and CEO of Rise Therapeutics.  In his previous role as Senior Vice President & Chief Operating Officer at Amplimmune, Dr. Fanger helped to lead the $500 million acquisition by Medimmune/AstraZeneca in 2013. Prior to joining Amplimmune, Dr. Fanger was Vice President of Business Development at MacroGenics where he directed partnering activities that included establishing MacroGenics’ strategic alliance with Eli Lilly & Company. Before MacroGenics, Dr. Fanger was responsible for a diverse array of corporate functions at Corixa Corporation, including heading up business development activities, establishing and directing the therapeutic antibody development program, and managing numerous pharma strategic alliances. Dr. Fanger has co-authored over 45 articles, book chapters and reviews in peer-reviewed journals in the areas of monoclonal antibody development, cell biology and cancer research. He has also been awarded 35 patents. Dr. Fanger received his MBA from Seattle University, PhD in Molecular and Cellular Biology from Dartmouth Medical School, and his BS in Chemistry from Denison University.